A new oral GLP-1 pill: what the aleniglipron phase 2b trial found

Aleniglipron (also known by its development code, GSBR-1290) is an investigational GLP-1 receptor agonist developed by Gasherbrum Bio, a subsidiary of Structure Therapeutics, for chronic weight management. GLP-1 receptor agonists are the same drug class behind semaglutide and tirzepatide, and our existing coverage of GLP-1 medications covers how that class works and what the approved drugs have shown in their own trials. What sets aleniglipron apart is its chemistry: it is a small molecule rather than a peptide, meaning it is structurally simpler and can be manufactured more like a conventional pill.^[2]

Semaglutide (Wegovy) and tirzepatide (Zepbound) are peptide drugs, chains of amino acids that break down in the digestive tract, which is why they are given by weekly injection rather than as a pill. Aleniglipron is a small molecule, the same broad chemical category as aspirin or common blood pressure medications, and is taken orally once a day. According to Robert Kushner, MD, a study co-author and professor emeritus of medicine at Northwestern University Feinberg School of Medicine, “the difference with aleniglipron is it’s a small molecule, which means it’s chemically made and could be taken with or without food.”^[5]

Small-molecule GLP-1 drugs are generally expected to be cheaper and easier to manufacture at scale than injectable peptides, and an oral option removes the need for injections, which matters to some patients. Neither of those potential advantages has been demonstrated in this trial; they are structural and manufacturing differences, not efficacy findings.

The trial, registered as NCT06693843 and published in Nature Medicine in June 2026, randomized 230 adults with obesity or overweight (mean BMI 39.5, 54% women) at 38 US medical centers to once-daily oral aleniglipron, dosed up to 45mg, 90mg, or 120mg with doses escalated every four weeks, or to a matching placebo, in a double-blind design.^[1][2]

At the 36-week primary endpoint, the trial met its primary goal: placebo-adjusted body-weight change was −8.2% at the 45mg dose, −9.8% at the 90mg dose, and −11.3% at the 120mg dose, with all three doses statistically significantly different from placebo (p<0.0001). The trial reported no apparent plateau in weight loss by the end of the double-blind period, and an ongoing open-label extension showed continued weight loss at an interim analysis around 20 weeks of median treatment duration.^[1]

For context, the phase 3 trials that supported approval of semaglutide and tirzepatide reported average weight loss in a broadly similar range at comparable time points, but those were larger, longer trials in different populations, so the numbers are not directly comparable across studies.^[3][4]

Gastrointestinal symptoms, the same category of side effects seen with injectable GLP-1 drugs, were the most common adverse events, described in the trial as generally mild to moderate and decreasing in frequency as the trial went on. About 10.4% of participants on aleniglipron discontinued treatment because of an adverse event, and the trial reported no cases of drug-induced liver injury.^[1][5]

A single phase 2b trial, however well designed, leaves real gaps. This trial does not include cardiovascular outcomes data, the kind of evidence that shaped the recent testosterone label changes we covered and that regulators typically expect before a chronic weight-management drug reaches approval. It also has not been replicated by an independent research team, does not report what happens to weight after people stop taking the drug (a question our GLP-1 coverage shows matters a great deal for semaglutide), and followed participants for well under a year, short relative to obesity as a long-term condition.

Aleniglipron is not FDA approved for any use. Structure Therapeutics has indicated, through its own disclosures, that it intends to move the drug into phase 3 testing, the larger, longer studies that precede an approval application, with dose-escalation adjustments aimed at improving tolerability.^[5] Phase 3 programs in obesity typically run one to two years or longer before results are available, and a substantial share of drugs that succeed in phase 2 do not ultimately reach approval on the same timeline or with the same profile suggested by earlier data. There is currently no FDA-reviewed timeline for when, or whether, aleniglipron will be approved.

Because aleniglipron is not an approved medication, it cannot legally be dispensed by a pharmacy or prescribed by a clinician in the United States. Products marketed online under this name are not regulated pharmaceuticals; their actual contents, dosing, and purity cannot be verified, which is the same caution our coverage of unregulated research peptides raises about compounds sold outside the approved-drug system.

Aleniglipron’s phase 2b results are genuinely notable: a peer-reviewed, placebo-controlled trial found a daily pill produced double-digit percentage weight loss in a population with obesity, using a chemically simpler drug class than the injectable GLP-1 medications already on the market. That is a real, well-sourced finding, and it is also, honestly, preliminary. One 230-person trial with 36 weeks of double-blind data does not establish long-term safety, cardiovascular effects, or how the drug compares head-to-head with approved options, and it has not yet been reviewed by the FDA. See how we grade evidence strength across topics in our editorial and evidence standards, and follow our Weight & Metabolic Health coverage as the phase 3 program develops.

Nothing here is a reason to seek out an unapproved compound. For anyone considering weight-management medication today, the relevant options remain the currently approved GLP-1 drugs, discussed with a prescribing clinician who can weigh your own health history against the actual evidence base.